IN8bio to Present at November Investor Conferences
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, CEO and co-founder, will be presenting at two investor conferences in November.
Related news for (INAB)
- IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
- IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
- MoBot’s Stock Market Highlights – 05/30/25 06:00 AM
- MoBot alert highlights: NASDAQ: FAAS, NASDAQ: BMGL, NASDAQ: INAB, NASDAQ: BSLK, NASDAQ: ECDA (05/30/25 05:00 AM)
- Today’s Top Performers: MoBot’s Market Review 05/30/25 04:00 AM